Genzyme's Lemtrada Approved in Canada for Treatment of MS

By: Benzinga
Genzyme, a Sanofi company (NYSE: SNY ), announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis (RRMS),
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.